LCTX

MKT CAP:$332M

Lineage Cell Therapeutics Inc

Market Cap

$332M

Healthcare·Biotechnology·🇺🇸 United States·AMEX

Healthcare·Biotechnology·🇺🇸·AMEX

Stock Price

$1.19-$0.45 (-27.44%)

Jun 5, 2026

52W High $1.9652W Low $0.68

Company Details

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal...

CEO

—

IPO Date

Mar 6, 1992

Website

www.lineagecell.com

Key Metrics TTM

Revenue

$15M

+54.6% YoY

Net Income

-$64M

EPS (Diluted)

Free Cash Flow

-$22M

Revenue / Share

$0.06

Gross Margin

98.0%

Operating Margin

-255.1%

Net Margin

-434.4%

FCF Margin

-150.9%

P/S

22.4x

P/E

Earnings Reports

Q2 2026

Aug 11, 2026

PENDING

Q1 2026

May 12, 2026

$2M+14.8%

FY 2025

Mar 5, 2026

$15M+53.2%

Q4 2025

Mar 5, 2026

$7M+130.4%

Q3 2025

Nov 6, 2025

$4M-2.6%

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee